Literature DB >> 6848742

Disposition of caffeine and its metabolites in man.

D D Tang-Liu, R L Williams, S Riegelman.   

Abstract

The disposition of caffeine and its metabolites was studied in six healthy subjects by use of sensitive and specific assays. The primary degradation of caffeine in man was found to be N-demethylation and/or ring oxidation to theophylline, paraxanthine, theobromine and 1,3,7-trimethyluric acid. These compounds were further degraded to dimethylated uric acids, monomethylxanthines and monomethyluric acids. About 3 and 6% of the drug was converted to theophylline and theobromine, respectively. The elimination of paraxanthine after its formation did not follow linear kinetics. A large urine recovery of 1-methylxanthine after caffeine administration in comparison with the amount recovered after administration of theophylline suggests an inhibitory effect on the degradation of this metabolite by either caffeine itself or another metabolite of caffeine. Caffeine and its primary metabolites, dimethylxanthines, were extensively reabsorbed in the renal tubule. Their renal clearances were highly urine flow-dependent and their urinary excretion varied with urine output during the study. About 70% of the dose was recovered in the urine. Postulated degradation pathways of caffeine are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848742

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  Effect of caffeine on clozapine pharmacokinetics in healthy volunteers.

Authors:  S Hägg; O Spigset; T Mjörndal; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

2.  A study on the route of 1-methylurate formation in theophylline metabolism.

Authors:  C Bayar; I Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

3.  Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  T B Vree; M Martea; R G Tiggeler; Y A Hekster; J C Hafkenscheid
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

4.  Factors influencing the caffeine test for cytochrome P 448-dependent liver function.

Authors:  R Joeres; H Klinker; H Huesler; J Epping; G Hofstetter; D Drost; H Reuss; W Zilly; E Richter
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

5.  Comparison of the urinary metabolite profile of caffeine in young and elderly males.

Authors:  J Blanchard; S J Sawers; J H Jonkman; D D Tang-Liu
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

Review 6.  Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease.

Authors:  Simonetta Camandola; Natalie Plick; Mark P Mattson
Journal:  Neurochem Res       Date:  2018-02-08       Impact factor: 3.996

7.  Novel modulators of poly(ADP-ribose) polymerase.

Authors:  Csaba Szabo; Pal Pacher; Raymond A Swanson
Journal:  Trends Pharmacol Sci       Date:  2006-10-19       Impact factor: 14.819

8.  Caffeine and paraxanthine pharmacokinetics in the rabbit: concentration and product inhibition effects.

Authors:  S H Dorrbecker; R A Ferraina; B R Dorrbecker; P A Kramer
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

9.  International society of sports nutrition position stand: caffeine and performance.

Authors:  Erica R Goldstein; Tim Ziegenfuss; Doug Kalman; Richard Kreider; Bill Campbell; Colin Wilborn; Lem Taylor; Darryn Willoughby; Jeff Stout; B Sue Graves; Robert Wildman; John L Ivy; Marie Spano; Abbie E Smith; Jose Antonio
Journal:  J Int Soc Sports Nutr       Date:  2010-01-27       Impact factor: 5.150

10.  Effects of caffeine on alertness.

Authors:  A Zwyghuizen-Doorenbos; T A Roehrs; L Lipschutz; V Timms; T Roth
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.